Literature DB >> 24711458

Topological localization of monomeric C-reactive protein determines proinflammatory endothelial cell responses.

Hai-Yun Li1, Jing Wang1, Yue-Xin Wu1, Lin Zhang1, Zu-Pei Liu1, János G Filep2, Lawrence A Potempa3, Yi Wu4, Shang-Rong Ji5.   

Abstract

The activation of endothelial cells (ECs) by monomeric C-reactive protein (mCRP) has been implicated in contributing to atherogenesis. However, the potent proinflammatory actions of mCRP on ECs in vitro appear to be incompatible with the atheroprotective effects of mCRP in a mouse model. Because mCRP is primarily generated within inflamed tissues and is rapidly cleared from the circulation, we tested whether these discrepancies can be explained by topological differences in response to mCRP within blood vessels. In a Transwell culture model, the addition of mCRP to apical (luminal), but not basolateral (abluminal), surfaces of intact human coronary artery EC monolayers evoked a significant up-regulation of MCP-1, IL-8, and IL-6. Such polarized stimulation of mCRP was observed consistently regardless of EC type or experimental conditions (e.g. culture of ECs on filters or extracellular matrix-coated surfaces). Accordingly, we detected enriched lipid raft microdomains, the major surface sensors for mCRP on ECs, in apical membranes, leading to the preferential apical binding of mCRP and activation of ECs through the polarized induction of the phospholipase C, p38 MAPK, and NF-κB signaling pathways. Furthermore, LPS and IL-1β induction of EC activation also exhibited topological dependence, whereas TNF-α did not. Together, these results indicate that tissue-associated mCRP likely contributes little to EC activation. Hence, topological localization is an important, but often overlooked, factor that determines the contribution of mCRP and other proinflammatory mediators to chronic vascular inflammation.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Atherosclerosis; C-Reactive Protein; Endothelial Dysfunction; Inflammation; Innate Immunity; Pentraxins; Polarized Activation

Mesh:

Substances:

Year:  2014        PMID: 24711458      PMCID: PMC4022894          DOI: 10.1074/jbc.M114.555318

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

Review 1.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

2.  Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice.

Authors:  Susanne B Schwedler; Kerstin Amann; Konstanze Wernicke; Alexander Krebs; Matthias Nauck; Christoph Wanner; Lawrence A Potempa; Jan Galle
Journal:  Circulation       Date:  2005-08-08       Impact factor: 29.690

3.  Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils.

Authors:  Tarek Khreiss; Levente József; Lawrence A Potempa; János G Filep
Journal:  Circ Res       Date:  2005-08-25       Impact factor: 17.367

4.  Tubular staining of modified C-reactive protein in diabetic chronic kidney disease.

Authors:  Susanne B Schwedler; Frank Guderian; Jobst Dämmrich; Lawrence A Potempa; Christoph Wanner
Journal:  Nephrol Dial Transplant       Date:  2003-11       Impact factor: 5.992

5.  Toll-like receptor 4 functions intracellularly in human coronary artery endothelial cells: roles of LBP and sCD14 in mediating LPS responses.

Authors:  Stefan Dunzendorfer; Hyun-Ku Lee; Katrin Soldau; Peter S Tobias
Journal:  FASEB J       Date:  2004-05-07       Impact factor: 5.191

6.  Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells.

Authors:  Tarek Khreiss; Levente József; Lawrence A Potempa; János G Filep
Journal:  Circulation       Date:  2004-03-29       Impact factor: 29.690

7.  Biodistribution and clearance of 125I-labeled C-reactive protein and 125I-labeled modified C-reactive protein in CD-1 mice.

Authors:  M Motie; K W Schaul; L A Potempa
Journal:  Drug Metab Dispos       Date:  1998-10       Impact factor: 3.922

8.  Genetically elevated C-reactive protein and ischemic vascular disease.

Authors:  Jeppe Zacho; Anne Tybjaerg-Hansen; Jan Skov Jensen; Peer Grande; Henrik Sillesen; Børge G Nordestgaard
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

9.  Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation.

Authors:  Martha Triantafilou; Kensuke Miyake; Douglas T Golenbock; Kathy Triantafilou
Journal:  J Cell Sci       Date:  2002-06-15       Impact factor: 5.285

10.  Plasmalemmal proteins of cultured vascular endothelial cells exhibit apical-basal polarity: analysis by surface-selective iodination.

Authors:  W A Muller; M A Gimbrone
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

View more
  17 in total

1.  An Intrinsically Disordered Motif Mediates Diverse Actions of Monomeric C-reactive Protein.

Authors:  Hai-Yun Li; Jing Wang; Fan Meng; Zhe-Kun Jia; Yang Su; Qi-Feng Bai; Ling-Ling Lv; Fu-Rong Ma; Lawrence A Potempa; Yong-Bin Yan; Shang-Rong Ji; Yi Wu
Journal:  J Biol Chem       Date:  2016-02-23       Impact factor: 5.157

2.  Bilateral photoplethysmography for arterial steal detection in arteriovenous fistula using a fractional-order decision-making quantizer.

Authors:  Jian-Xing Wu; Guan-Chun Chen; Ming-Jui Wu; Chia-Hung Lin; Tainsong Chen
Journal:  Med Biol Eng Comput       Date:  2016-05-06       Impact factor: 2.602

Review 3.  Regulation of Conformational Changes in C-reactive Protein Alters its Bioactivity.

Authors:  Naeem Ullah; Yi Wu
Journal:  Cell Biochem Biophys       Date:  2022-08-23       Impact factor: 2.989

4.  C-reactive protein directly suppresses Th1 cell differentiation and alleviates experimental autoimmune encephalomyelitis.

Authors:  Lin Zhang; Shan-Hui Liu; Tyler T Wright; Zhi-Yuan Shen; Hai-Yun Li; Wei Zhu; Lawrence A Potempa; Shang-Rong Ji; Alexander J Szalai; Yi Wu
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

Review 5.  Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes.

Authors:  J R Thiele; J Zeller; H Bannasch; G B Stark; K Peter; S U Eisenhardt
Journal:  Mediators Inflamm       Date:  2015-05-18       Impact factor: 4.711

6.  Mutations of C-reactive protein (CRP) -286 SNP, APC and p53 in colorectal cancer: implication for a CRP-Wnt crosstalk.

Authors:  Hai-Xiang Su; Hai-Hong Zhou; Ming-Yu Wang; Jin Cheng; Shi-Chao Zhang; Feng Hui; Xue-Zhong Chen; Shan-Hui Liu; Qin-Jiang Liu; Zi-Jiang Zhu; Qing-Rong Hu; Yi Wu; Shang-Rong Ji
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

7.  Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites.

Authors:  David Braig; Tracy L Nero; Hans-Georg Koch; Benedict Kaiser; Xiaowei Wang; Jan R Thiele; Craig J Morton; Johannes Zeller; Jurij Kiefer; Lawrence A Potempa; Natalie A Mellett; Luke A Miles; Xiao-Jun Du; Peter J Meikle; Markus Huber-Lang; G Björn Stark; Michael W Parker; Karlheinz Peter; Steffen U Eisenhardt
Journal:  Nat Commun       Date:  2017-01-23       Impact factor: 14.919

8.  Monomeric C-Reactive Protein Binds and Neutralizes Receptor Activator of NF-κB Ligand-Induced Osteoclast Differentiation.

Authors:  Zhe-Kun Jia; Hai-Yun Li; Yu-Lin Liang; Lawrence Albert Potempa; Shang-Rong Ji; Yi Wu
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

9.  The role of complement activation in rhabdomyolysis-induced acute kidney injury.

Authors:  XuDong Huang; Wei Zhao; LiXia Zhang; XinJun Yang; LiHui Wang; YunShuang Chen; JingHua Wang; Chao Zhang; GuangLi Wu
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

Review 10.  C-Reactive Protein in Atherothrombosis and Angiogenesis.

Authors:  Lina Badimon; Esther Peña; Gemma Arderiu; Teresa Padró; Mark Slevin; Gemma Vilahur; Gemma Chiva-Blanch
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.